AstraZeneca Invests $100 Million To Expand Shanghai Site In Move To Capture Larger Share Of Emerging Markets

SHANGHAI - AstraZeneca is investing $100 million to expand its current site in the Shanghai Zhangjiang Hi-Tech Park to strengthen its China headquarters and beef up marketing, R&D and academic training